Biologic Treatment Options for Retinal Neovascularization in Behçet’s Disease

REFERENCES

• Sakane T, Takeno M, Suzuki N, et al. Behcet’s disease. N Engl J Med. 1999 Oct 21;341(17):1284–1291.
   PubMed Web of Science ®Google Scholar
• Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. 2001 Nov-Dec;46(3):209–233.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behcet’s disease. International study group for Behcet’s disease. Lancet. 1990 May 5;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Mamo JG. The rate of visual loss in Behcet’s disease. Arch Ophthalmol. 1970 Oct;84(4):451–452.
   PubMedGoogle Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet disease: An analysis of 880 patients. Am J Ophthalmol. 2004 Sep;138(3):373–380.
   PubMed Web of Science ®Google Scholar
• Accardo-Palumbo A, Giardina AR, Ciccia F, et al. Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behcet’s disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther. 2010;12(3):R109.
   PubMed Web of Science ®Google Scholar
• Sugita S, Kawazoe Y, Imai A, et al. Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet’s disease. J Immunol. 2013 Jun 1;190(11):5799–5808.
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behcet’s disease. Invest Ophthalmol Vis Sci. 2011 Jan;52(1):476–484.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001 Jul 28;358(9278):295–296.
   PubMed Web of Science ®Google Scholar
• Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behcet’s disease. Lancet. 2001 Nov 10;358(9293):1644.
   PubMed Web of Science ®Google Scholar
• Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003 Jul;110(7):1449–1453.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: An open-label trial. Arthritis Rheum. 2005 Aug;52(8):2478–2484.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: A comparative 4-week study. Rheumatology (Oxford). 2011 Mar;50(3):593–597.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: A pilot study in 15 patients. Am J Ophthalmol. 2012 Sep;154(3):534–41 e1.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004 Mar 2;140(5):404–406.
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behcet’s uveitis: An open-label trial. Rheumatol Int. 2008 Nov;29(1):53–57.
   PubMed Web of Science ®Google Scholar
• Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet’s disease. Clin Exp Rheumatol. 2004 Jul-Aug;22(4 Suppl 34):S14–6.
   Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012 May;130(5):592–598.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet’s disease: A multicenter study. Ophthalmology. 2014 Oct;121(10):1877–1884.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: A 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014 Dec;53(12):2223–2231.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet’s disease–review and basis for recommendations. Rheumatology (Oxford). 2007 May;46(5):736–741.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behcet’s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014 Jan;58(1):75–80.
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcet’s disease: Analysis of published data on 369 patients. Semin Arthritis Rheum. 2011 Aug;41(1):61–70.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2005 Jul-Aug;50(4):297–350.
   PubMed Web of Science ®Google Scholar
• Androudi S. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2006 Mar-Apr;51(2):174. author reply−7.
   Web of Science ®Google Scholar
• Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology. 2012 Aug;119(8):1575–1581.
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet’s disease: Experience in 19 patients. Rheumatology (Oxford). 2012 Oct;51(10):1825–1831.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar;121(3):785–96 e3.
   PubMed Web of Science ®Google Scholar
• Graham EM, Stanford MR, Shilling JS, et al. Neovascularisation associated with posterior uveitis. Br J Ophthalmol. 1987 Nov;71(11):826–833.
   PubMed Web of Science ®Google Scholar
• Sanislo SR, Lowder CY, Kaiser PK, et al. Corticosteroid therapy for optic disc neovascularization secondary to chronic uveitis. Am J Ophthalmol. 2000 Dec;130(6):724–731.
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Weiter JJ. Resolution of optic disk neovascularization associated with intraocular inflammation. Am J Ophthalmol. 1980 Oct;90(4):545–548.
   PubMed Web of Science ®Google Scholar
• Pach JM, Herman DC, Garrity JA, et al. Disk neovascularization in chronic anterior uveitis. Am J Ophthalmol. 1991 Feb 15;111(2):241–243.
   PubMed Web of Science ®Google Scholar
• Atmaca LS, Batioglu F, Idil A. Retinal and disc neovascularization in Behcet’s disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1996 Feb;234(2):94–99.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behcet’s disease. Jpn J Ophthalmol. 2006 May-Jun;50(3):256–265.
   PubMed Web of Science ®Google Scholar
• Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine. 2003 Dec 7;24(5):210–218.
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: Review of the literature. Semin Arthritis Rheum. 2004 Apr;33(5):320–335.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Barbera ML, Virgili G, et al. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol. 2004 Sep-Oct;14(5):445–448.
   Web of Science ®Google Scholar
• Kawaguchi T, Sugita S, Yamada Y, et al. Regression of optic disc neovascularization in patients with Behcet’s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther. 2010 Dec;26(6):627–630.
   PubMed Web of Science ®Google Scholar
• Park JY, Chung YR, Lee K, et al. Clinical experience of interferon Alfa-2a treatment for refractory uveitis in Behcet’s disease. Yonsei Med J. 2015 Jul;56(4):1158–1162.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010 Sep;62(9):2796–2805.
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003 Apr;87(4):423–431.
   PubMed Web of Science ®Google Scholar
• Kotter I, Deuter C, Stubiger N, et al. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behcet’s disease: focusing more on IFN. J Rheumatol. 2005 Aug;32(8):1633. author reply 4.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1692–1695.
   PubMed Web of Science ®Google Scholar
• Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol. 2000 Dec;84(12):1437–1438.
   PubMed Web of Science ®Google Scholar